Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.67 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.64 |
| ▸ | DRD4 | P21917 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.60 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.60 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.60 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.60 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.60 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.60 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3664764 | 0.89 | CHRM2 (0.55) | CHRM2CHRM1SLC6A5CHRM4DRD4 | |
| SCHEMBL23744108 | 0.88 | CHRM2 (0.76) | CHRM2CHRM1SLC6A5CHRM4DRD4 | |
| SCHEMBL62082 | 0.87 | SLC6A5 (0.81) | SLC6A5CHRM4DRD4DRD2MEN1 | |
| SCHEMBL7214415 | 0.85 | DRD4 (0.81) | SLC6A5CHRM4DRD4DRD2MEN1 | |
| SCHEMBL61850 | 0.84 | DRD2 (0.66) | SLC6A5DRD4DRD2MEN1KMT2A | |
| SCHEMBL1036032 | 0.84 | PRKAA2 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL61848 | 0.82 | TMEM97 (0.83) | DRD4DRD2MEN1KMT2ASIGMAR1 | |
| SCHEMBL29432226 | 0.80 | CHRM2 (1.00) | CHRM2CHRM1CHRM4CHRM5CHRM3 | |
| SCHEMBL23744053 | 0.79 | CHRM2 (0.68) | CHRM2CHRM1CHRM4PRKAA2CHRM5 | |
| SCHEMBL29432151 | 0.78 | CHRM4 (1.00) | CHRM2CHRM1CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231666-B1 | Carboxamide, sulfonamide and amine compounds for metabolic disorders | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | claimed |
| US-8557822-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | claimed |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | claimed |
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | claimed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | claimed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2231666-B1 | Carboxamide, sulfonamide and amine compounds for metabolic disorders | RIGEL PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129390-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | CHRM2 1726/4885CHRM1 2777/4885SLC6A5 3833/4885 |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | CHRM2 607/4885CHRM1 998/4885SLC6A5 4540/4885 |
| US-20090163511-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | CHRM2 607/4885CHRM1 998/4885SLC6A5 4540/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | CHRM2 1418/4885CHRM1 2050/4885SLC6A5 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.